Verification Checklist for Buyers of GLP-1-Class Research Compounds
Updated August 23, 2026
Five properties of a GLP-1-class research-compound seller can be verified from public records and the seller's own pages before any order: the legal entity behind the site, its FDA warning-letter history, its cart contents, its product-page language, and its testing documentation. Two of the five restate documented findings from FDA's 2024–2026 letters.
The five criteria
| Criterion | What to verify | Origin of the criterion |
|---|---|---|
| 1. Named legal entity | The site identifies the registered company behind the brand, not only a brand name. | FDA letters are addressed to registered entities with their trade names — Lovega LLC dba Pink Pony Peptides, Prime Vitality Inc dba Prime Peptides. Matching a storefront to any public record requires the legal name. |
| 2. Warning-letter history | Both the brand name and the registered name, searched in FDA's warning-letter database. | The database is the primary public record; every letter this index tracks is retrievable there by recipient name. |
| 3. Cart contents | Whether administration supplies are offered in the same cart as the compounds. | A documented finding of the March 31, 2026 letters, where cart composition itself entered the record as intended-use evidence. |
| 4. Product-page language | Whether listings describe what a compound does in a human subject. | A documented finding in both the December 2024 and March 2026 batches, and the category FDA weighed directly against research-use disclaimers. |
| 5. Testing documentation | Whether a certificate of analysis is offered for the material sold. | This index's own documentation criterion — the only item on the list that concerns the material rather than the marketing. |
Which criteria the letters wrote
Criteria three and four are not this index's invention; they restate what the agency itself reviewed. The GLP-1-class batch of December 10, 2024 was built on seller-published evidence read against research-use labels, and the March 31, 2026 letters added the cart finding and stated the agency's position on disclaimers in terms the letters quote directly: "evidence obtained from your website establishes that your products are intended to be drugs for human use." Criterion one comes from the address blocks of those same letters, where registered names and trade names appear together. Criteria two and five are the index's own — one a search of the public record, one a question about documentation — and they are labeled as such rather than dressed as agency findings.
What five passed checks produce
A profile, not an endorsement. A seller clearing every criterion has a public footprint that, on these five axes, does not match the footprints described in the 2024–2026 letters — a factual statement about published pages and public records, with no agency clearance implied and none available. A seller failing the third or fourth check has the opposite profile: a footprint matching a documented letter finding. This index recommends no seller, ranks none, and maintains no roster of acceptable ones; the checklist ends where it ends, and the decision that follows belongs to the buyer.
Scope note
The criteria are stated for GLP-1-class compounds because that is the class the December 2024 batch shares and the class where enforcement records are densest, but nothing in the five checks is class-specific — each reads a seller's pages and the public record, not the chemistry. Entity-level records behind the criteria — the letters, the raid, the closures, the sentencing — are collected in the vendor index.
Sources
- FDA Warning Letters index (searchable by recipient name). fda.gov
- FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
- FDA Warning Letter, Prime Vitality Inc dba Prime Peptides, 695156-12102024. fda.gov
- FDA Warning Letter, Xcel Research LLC, 694608-12102024. fda.gov
- FDA Warning Letter, Lovega LLC dba Pink Pony Peptides, 721088-03312026 (the administration-supplies finding, March 2026 batch). fda.gov
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.